Name: APELLIS PHARMACEUTICALS INC (APLS) Stock
Brand: APELLIS PHARMACEUTICALS INC
Rating: 4.5 (3 reviews)

APLS Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Chartmill

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Presents an Affordable Growth Opportunity

19 days ago - By: Chartmill - Mentions: FMC FMFC EBS GCI ...

These stocks are moving in today's session

6 days ago - By: Benzinga

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power

6 days ago - By: Apellis Pharmaceuticals, Inc.

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

6 days ago - By: Apellis Pharmaceuticals, Inc.

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

12 days ago - By: Benzinga - Mentions: BJRI EAT GLXY ABVX

This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

13 days ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

13 days ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

18 days ago - By: Zacks Investment Research - Mentions: BEAM FOLD ANIP

Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates

19 days ago - By: Chartmill - Mentions: FMC FMFC EBS HBIO ...

Here are the top movers in Thursday's session.

19 days ago - By: Chartmill - Mentions: FMC FMFC EBS IART ...

The market is filled with gapping stocks in Thursday's session.

19 days ago - By: Zacks Investment Research

Apellis Pharmaceuticals (APLS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

19 days ago - By: Chartmill

Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reports Strong Q3 2025 Earnings Beat

20 days ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

20 days ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

a month ago - By: Zacks Investment Research - Mentions: RGEN

Apellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth

a month ago - By: Apellis Pharmaceuticals, Inc.

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

a month ago - By: Apellis Pharmaceuticals, Inc.

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

a month ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

a month ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

3 months ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

3 months ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

3 months ago - By: Stocktwits

Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary

4 months ago - By: Yahoo Finance - Mentions: NVS C NOVN

Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target

4 months ago - By: Stocktwits - Mentions: GS MS

APELLIS PHARMACEUTICALS INC (APLS) Stock News

APLS Latest News, Press Relases and Analysis

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Presents an Affordable Growth Opportunity

These stocks are moving in today's session

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates

Here are the top movers in Thursday's session.

The market is filled with gapping stocks in Thursday's session.

Apellis Pharmaceuticals (APLS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reports Strong Q3 2025 Earnings Beat

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Apellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary

Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target

Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug